Piramal Pharma Solutions, a contract development and manufacturing organisation, has announced an $80m investment to expand its sterile injectables facility in Lexington, Kentucky, in the US. The expansion aims to bolster the company's manufacturing capabilities and capacity to meet the increasing market demand for sterile injectable drug products.

Piramal Pharma Solutions Inc. today announced plans to expand its current Lexington operations with a nearly $80 million investment creating 45 new full-time jobs in the area.

Piramal Pharma Solutions (PPS), the global contract manufacturing division of Piramal Pharma Ltd, is set to invest $80 million in expanding its sterile injectables facility in Lexington, Kentucky. Piramal's global Contract Development and Manufacturing ...

Piramal Pharma Solutions, is investing $80 million to expand its Lexington facility, doubling capacity by Q1 2027 to meet growing injectables demand, supporting its ADC manufacturing program.

Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma

The expansion will equip the Lexington site with an additional 24,000 square feet of manufacturing space, a new lab, and state‐of‐the‐art machinery.

The investment has been financed through bank loans and internal accruals, and aims to enhance site’s capacity to meet rising demand, said the company.

Piramal Pharma’s stock price rose 2% in the opening trading on September 30 after the business received an Establishment Inspection Report (EIR) for its production facility in Ahmedabad, India. The USFDA examined the plant in July 2024 and issued a No Action Indicated (NAI) classification based on Zero Form – 483 observations.

Piramal Pharma Solutions invests $80 million in Lexington facility expansion to meet growing demand in injectables market.